Is compounded tirzepatide legal in 2026?
Compounded tirzepatide and semaglutide are not FDA-approved, and as of November 20, 2026 they reach U.S. patients as prescriptions for an individual patient filled by state-licensed 503A compounding pharmacies; they are made with the drug in Zepbound or Wegovy but are not the same product. FDA proposed on April 30, 2026 not to place either drug on the 503B bulks list, and no final decision was found as of November 20. Warning letters continue, including letter 737905 to telehealth seller RonanRx on October 30, 2026.
Released · Last reviewed · how we verify
Limitations of this answer
Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy. This page reports prices and terms; whether any GLP-1 suits you is a decision for you and a licensed clinician.
Frequently asked
Is compounded tirzepatide legal in 2026?
Compounded tirzepatide and semaglutide are not FDA-approved, and as of November 20, 2026 they reach U.S. patients as prescriptions for an individual patient filled by state-licensed 503A compounding pharmacies; they are made with the drug in Zepbound or Wegovy but are not the same product. FDA proposed on April 30, 2026 not to place either drug on the 503B bulks list, and no final decision was found as of November 20. Warning letters continue, including letter 737905 to telehealth seller RonanRx on October 30, 2026.
How current are the prices on TopGLP1Providers?
Every price on TopGLP1Providers carries the date it was read on the program’s own page; the whole dataset was re-read on November 20, 2026, from 2026-11-21 00:33 to 00:57 UTC, and NexLife’s plan pages were checked again for this site on November 21 (UTC). Programs whose pages refused automated reads that day, such as TrimRx, MEDVi, bmiMD, Embody, Ro and Hims & Hers, show no current price rather than an older one. When a program changes its price, the record, the pages that cite it and the changelog are updated together.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)